Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 1999

View Archived Issues

Company Profile: Ranbaxy

Positive results shown in phase III interim analysis of Neutralase

Discovery receives Cystic Fibrosis Foundation grant for SuperVent

New company formed to develop therapeutic proteins with prolonged activity

Mallinckrodt to market Palatin Technologies' infection imaging agent

Long-term Aricept treatment improves cognitive function, prevents decline in patients with AD

Xoma: Q2 1999 highlights

Gliatech's IDE for ADCON-L approved by FDA

Diatide highlights Q2 1999 activities

Anesta seeks approval for Actiq in the U.K.

ImmGenics' SLAM technology presented at conference

EUK-134 protects against neuronal damage in seizure model

Known anti-HIV compound also shows potential in treating immune disorders

Zenyaku Kogyo will develop and market novel psoriasis treatment in Japan

RWJ-56110: first report of a new antithrombotic targeting the PAR-1 receptor

Yakult Honsha discloses potent and water-soluble taxane derivatives

Novel antimycotic agent TRK-2999 isolated from a fungal strain

SRL-172 shows promising initial results in phase I/II asthma trial

Clinical trials of SRL-172 in lung cancer are progressing

Pfizer investigates ORL1 agonists with analgesic activity in rodent models

Neurokinin receptors with broad potential utility discovered at Schering-Plough

Sumitomo research provides new interferon inducers

Chugai continues to investigate new vitamin D compounds

Sanofi researchers modify heparin structure to improve on therapeutic properties

Factor Xa inhibitor HMR-2906 is more effective and safer than hirudin in dog model of thrombosis

Servier's novel approach to antiplatelet therapy: dual TP antagonists/NO donors

Agouron commences phase III trial of prinomastat for treatment of lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...